关注
Hiroyoshi Nishikawa
Hiroyoshi Nishikawa
国立がん研究センター 研究所 分野長
在 ncc.go.jp 的电子邮件经过验证
标题
引用次数
引用次数
年份
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
K Atarashi, T Tanoue, K Oshima, W Suda, Y Nagano, H Nishikawa, ...
Nature 500 (7461), 232-236, 2013
30142013
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato, SH Olson, J Ahn, B Bundy, H Nishikawa, F Qian, AA Jungbluth, ...
Proceedings of the National Academy of Sciences 102 (51), 18538-18543, 2005
28312005
Regulatory T cells in tumor immunity
H Nishikawa, S Sakaguchi
International journal of cancer 127 (4), 759-767, 2010
12122010
Regulatory T cells in cancer immunosuppression—implications for anticancer therapy
Y Togashi, K Shitara, H Nishikawa
Nature reviews Clinical oncology 16 (6), 356-371, 2019
11472019
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Y Ohue, H Nishikawa
Cancer science 110 (7), 2080-2089, 2019
8502019
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
T Kamada, Y Togashi, C Tay, D Ha, A Sasaki, Y Nakamura, E Sato, ...
Proceedings of the National Academy of Sciences 116 (20), 9999-10008, 2019
8042019
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
T Saito, H Nishikawa, H Wada, Y Nagano, D Sugiyama, K Atarashi, ...
Nature medicine 22 (6), 679-684, 2016
7712016
Regulatory T cells in cancer immunotherapy
H Nishikawa, S Sakaguchi
Current opinion in immunology 27, 1-7, 2014
7632014
Anti-CCR4 mAb selectively depletes effector-type FoxP3+ CD4+ regulatory T cells, evoking antitumor immune responses in humans
D Sugiyama, H Nishikawa, Y Maeda, M Nishioka, A Tanemura, ...
Proceedings of the National Academy of Sciences 110 (44), 17945-17950, 2013
6682013
Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)
S Fukuoka, H Hara, N Takahashi, T Kojima, A Kawazoe, M Asayama, ...
Journal of Clinical Oncology 38 (18), 2053-2061, 2020
5952020
Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation
M Matsumoto, A Baba, T Yokota, H Nishikawa, Y Ohkawa, H Kayama, ...
Immunity 41 (6), 1040-1051, 2014
5732014
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
S Kumagai, Y Togashi, T Kamada, E Sugiyama, H Nishinakamura, ...
Nature immunology 21 (11), 1346-1358, 2020
5712020
Roles of regulatory T cells in cancer immunity
Y Takeuchi, H Nishikawa
International immunology 28 (8), 401-409, 2016
5282016
NY‐ESO‐1: review of an immunogenic tumor antigen
S Gnjatic, H Nishikawa, AA Jungbluth, AO Güre, G Ritter, E Jäger, A Knuth, ...
Advances in cancer research 95, 1-30, 2006
4352006
Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut
K Kakihana, Y Fujioka, W Suda, Y Najima, G Kuwata, S Sasajima, ...
Blood, The Journal of the American Society of Hematology 128 (16), 2083-2088, 2016
3742016
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
S Kumagai, S Koyama, K Itahashi, T Tanegashima, Y Lin, Y Togashi, ...
Cancer Cell 40 (2), 201-218. e9, 2022
3602022
Natural and induced T regulatory cells in cancer
DO Adeegbe, H Nishikawa
Frontiers in immunology 4, 190, 2013
3022013
Tumor‐infiltrating IL‐17‐producing γδ T cells support the progression of tumor by promoting angiogenesis
D Wakita, K Sumida, Y Iwakura, H Nishikawa, T Ohkuri, K Chamoto, ...
European journal of immunology 40 (7), 1927-1937, 2010
2922010
CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses
H Nishikawa, T Kato, K Tanida, A Hiasa, I Tawara, H Ikeda, Y Ikarashi, ...
Proceedings of the National Academy of Sciences 100 (19), 10902-10906, 2003
2282003
Regulatory T cells: a potential target in cancer immunotherapy
K Shitara, H Nishikawa
Annals of the New York Academy of Sciences 1417 (1), 104-115, 2018
2202018
系统目前无法执行此操作,请稍后再试。
文章 1–20